

# Alessandro Parisi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9397800/alessandro-parisi-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37  
papers

394  
citations

8  
h-index

19  
g-index

41  
ext. papers

541  
ext. citations

3.6  
avg, IF

3.14  
L-index

#	Paper	IF	Citations
37	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable <b>2019</b> , 7, 57		155
36	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 347-351	3.2	38
35	High- and low-penetrance cutaneous melanoma susceptibility genes. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 657-70	3.5	37
34	Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1623-1630	3.2	26
33	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , <b>2019</b> , 10, 5926-5934	4.5	16
32	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
31	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 1427-1440	4.9	9
30	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , <b>2018</b> , 10, 643-655	3.8	9
29	Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy. <i>Indian Journal of Palliative Care</i> , <b>2017</b> , 23, 350-352	1.3	7
28	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
27	First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 158-162	3.6	7
26	Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 2159-2170	4.4	6
25	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolmmunology</i> , <b>2020</b> , 9, 1710389	7.2	6
24	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 2365-2373	4.9	6
23	What Is Known about Theragnostic Strategies in Colorectal Cancer. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	6
22	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. <i>Case Reports in Oncological Medicine</i> , <b>2019</b> , 2019, 3452762	0.9	5
21	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 1513-1527	3	4

20	Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 241-252	3.2	4
19	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. <i>Palliative and Supportive Care</i> , <b>2019</b> , 17, 82-86	2.5	4
18	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	4
17	The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , <b>2020</b> , 18, 33-38	2.5	4
16	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 712053	5.3	3
15	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
14	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
13	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. <i>Journal of Addictive Diseases</i> , <b>2020</b> , 38, 229-234	1.7	2
12	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , <b>2020</b> , 51, 1094-1101	1.6	2
11	Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. <i>Oncology Reports</i> , <b>2018</b> , 40, 803-812	3.5	2
10	The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A hypothesis-generator study from clinical practice. <i>Oncology Letters</i> , <b>2018</b> , 16, 7195-7203	2.6	2
9	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. <i>Case Reports in Oncological Medicine</i> , <b>2018</b> , 2018, 2783917	0.9	2
8	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. <i>Bioengineering</i> , <b>2019</b> , 6,	5.3	1
7	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , <b>2021</b> , 30, 2455	3.9	1
6	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. <i>Journal of Clinical Neuromuscular Disease</i> , <b>2018</b> , 20, 99-100	1.1	1
5	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.. <i>European Journal of Cancer</i> , <b>2022</b> , 170, 10-16	7.5	1
4	Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 863639	5.3	0
3	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 178-178	2.2	

- 2 Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives. *Journal of Thoracic Disease*, **2018**, 10, E520-E525 2.6
- 1 Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption. *Breast Disease*, **2021**, 40, 257-262 1.6